{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+DIPG", "query": { "condition": "Refractory DIPG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+DIPG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:22:23.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05956821", "title": "Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Fibrillary Astrocytomas", "Oligodendroglioma", "Diffuse Intrinsic Brainstem Glioma", "Diffuse Intrinsic Pontine Glioma", "DIPG Brain Tumor", "H3 K27M" ], "interventions": [ { "name": "SIACI of cetuximab and bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 20, "start_date": "2025-06-19", "completion_date": "2029-12-01", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05956821" }, { "nct_id": "NCT03478462", "title": "Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric Solid Tumor", "Pediatric Lymphoma", "Pediatric Brain Tumor", "DIPG", "Neuroblastoma", "Ewing Sarcoma", "Rhabdomyosarcoma", "Osteosarcoma" ], "interventions": [ { "name": "CLR 131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2019-04-30", "completion_date": "2027-02-25", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 6, "location_summary": "Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478462" }, { "nct_id": "NCT06521567", "title": "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Hodgkin Lymphoma", "High and Low Grade Glioma", "Glioblastoma Multiforme (GBM)", "Diffuse Intrinsic Pontine Glioma (DIPG)", "Ependymoma", "Osteosarcoma", "Hepatic Tumors", "Hepatoblastoma", "Hepatocellular Carcinoma (HCC)", "Fibrolamellar Carcinoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Cobolimab", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 83, "start_date": "2025-03-06", "completion_date": "2026-10-13", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 6, "location_summary": "Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06521567" }, { "nct_id": "NCT06838676", "title": "ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Gliomas (DIPG)", "Progressive DIPG", "Refractory DIPG", "Recurrent DIPG", "H3K27-altered High Grade Glioma" ], "interventions": [ { "name": "ACT001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Months to 39 Years" }, "enrollment_count": 60, "start_date": "2025-07-10", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 12, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06838676" }, { "nct_id": "NCT03389802", "title": "Phase I Study of APX005M in Pediatric Central Nervous System Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "High-grade Astrocytoma Not Otherwise Specified (NOS)", "CNS Primary Tumor, Not Otherwise Specified (NOS)", "Ependymoma, Not Otherwise Specified (NOS)", "Diffuse Intrinsic Pontine Gliomas (DIPG)", "Medulloblastoma" ], "interventions": [ { "name": "APX005M treatment for recurrent or refractory primary malignant CNS tumor patients", "type": "BIOLOGICAL" }, { "name": "APX005M treatment for newly diagnosed DIPG patients", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 32, "start_date": "2018-03-01", "completion_date": "2026-06-30", "has_results": true, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03389802" }, { "nct_id": "NCT01774253", "title": "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pontine Glioma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 9, "start_date": "2013-05", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Grand Rapids, Michigan", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01774253" }, { "nct_id": "NCT04730349", "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ependymoma", "Ewing Sarcoma", "High-grade Glioma", "Leukemia and Lymphoma", "Medulloblastoma", "Miscellaneous Brain Tumors", "Miscellaneous Solid Tumors", "Neuroblastoma", "Relapsed, Refractory Malignant Neoplasms", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "NKTR-214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 15, "start_date": "2021-06-03", "completion_date": "2022-06-22", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • St Louis, Missouri", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730349" }, { "nct_id": "NCT05768880", "title": "Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Diffuse Midline Glioma", "Recurrent CNS Tumor, Adult", "Recurrent, CNS Tumor, Childhood", "Refractory Primary Malignant Central Nervous System Neoplasm" ], "interventions": [ { "name": "SC-CAR4BRAIN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "26 Years", "sex": "ALL", "summary": "1 Year to 26 Years" }, "enrollment_count": 72, "start_date": "2023-05-05", "completion_date": "2043-12-31", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768880" }, { "nct_id": "NCT03538587", "title": "Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioblastomas", "Sarcoma", "Astrocytoma", "Brain Cancer", "Leukemia" ], "interventions": [ { "name": "Enhanced Mindfulness Intervention", "type": "BEHAVIORAL" }, { "name": "Psychoeducation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "5 Years to 24 Years" }, "enrollment_count": 10, "start_date": "2019-01-29", "completion_date": "2022-09-13", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538587" }, { "nct_id": "NCT02359565", "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-enhanced MR Perfusion", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 71, "start_date": "2015-06-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T22:22:23.543Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359565" } ] }